Compile Data Set for Download or QSAR
Report error Found 223 Enz. Inhib. hit(s) with all data for entry = 8946
TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430697(US10544150, Compound 63 | (3-(2-phenylthiazol-4-yl...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430696(US10544150, Compound 62 | (8-methyl-3-(2-phenylthi...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430699(US10544150, Compound 65 | (8-methyl-3-(quinolin-2-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430698(US10544150, Compound 64 | (8-methyl-3-(2-phenylthi...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430693(US10544150, Compound 59 | (3-(benzo[d]thiazol-2-yl...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430692(US10544150, Compound 58 | (3-(2-(2-chlorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430695(US10544150, Compound 61 | (4-fluorophenyl)(8-methy...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430694(US10544150, Compound 60 | (8,8-dimethyl-3-(2-pheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430689(US10544150, Compound 55 | (3-(2-morpholinothiazol-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430688(US10544150, Compound 54 | (3-(2-phenylthiazol-4-yl...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430691(US10544150, Compound 57 | (4-fluorophenyl)(3-(4-ph...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430690(US10544150, Compound 56 | (8-methyl-3-(2-morpholin...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430685(US10544150, Compound 51 | (4-fluorophenyl)(8-(2-hy...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430684(US10544150, Compound 50 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430687(US10544150, Compound 53 | (4'-fluoro-[1,1'-bipheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430686(US10544150, Compound 52 | (4-fluorophenyl)(8-methy...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430713(US10544150, Compound 79 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430712(US10544150, Compound 78 | (3-(2-(4-fluorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430714(US10544150, Compound 80 | (3-(2-(2,4-difluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430708(US10544150, Compound 74 | (3-(2-(2-chlorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430711(US10544150, Compound 77 | (3-(2-(2,4-difluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430710(US10544150, Compound 76 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430705(US10544150, Compound 71 | (R)-(4-fluorophenyl)(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430704(US10544150, Compound 70 | (4-fluorophenyl)(3-(2-(4...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430707(US10544150, Compound 73 | (3-(2-(4-fluorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430706(US10544150, Compound 72 | [1,1'-biphenyl]-4-yl(8-m...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430701(US10544150, Compound 67 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430700(US10544150, Compound 66 | (3-(2-(2-chlorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430703(US10544150, Compound 69 | (3-(quinolin-2-yl)-5,6-d...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430702(US10544150, Compound 68 | (R)-(3-(2-(4-chloropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430729(US10544150, Compound 112 | (4-chloro-3-fluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430728(US10544150, Compound 111 | (3-chloro-4-fluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430731(US10544150, Compound 114 | (8-methyl-3-(2-phenylox...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430730(US10544150, Compound 113 | (3-(2-(4-fluorophenyl)t...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430727(US10544150, Compound 110 | (3,4-difluorophenyl)(3-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430726(US10544150, Compound 109 | (3,4-dichlorophenyl)(3-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430717(US10544150, Compound 90 | (5-phenylpyridin-2-yl)(3...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430716(US10544150, Compound 85 | (8-methyl-3-(3-phenyl-1,...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430718(US10544150, Compound 91 | (6-phenylpyridin-3-yl)(3...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430741(US10544150, Compound 164 | (S)-(4-fluorophenyl)(3-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430747(US10544150, Compound 166 | (4-fluorophenyl)(8-meth...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430746(US10544150, Compound 165 | (S)-(3-(2-(2,4-difluoro...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430743(US10544150, Compound 162 | (S)-(4-fluorophenyl)(8-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430737(US10544150, Compound 136 | (R)-(8-methyl-3-(2-morp...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430736(US10544150, Compound 135 | (R)-(8-methyl-3-(2-phen...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081194(CHEMBL3422009 | US10544150, Compound 156)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430738(US10544150, Compound 144 | (R)-(8-methyl-3-(quinol...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430733(US10544150, Compound 118 | (R)-[1,1'-biphenyl]-4-y...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430732(US10544150, Compound 115 | (R)-(4-fluorophenyl)(8-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM430735(US10544150, Compound 134 | (R)-(4'-fluoro-[1,1'-bi...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

Displayed 1 to 50 (of 223 total ) | Next | Last >>
Jump to: